Mirum Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-158.56	-163.42	-135.67	-83.99	-103.27	-52.55
Depreciation & Amortization	15.63	11.45	3.68	0.98	0.62	0.32
Share-Based Compensation	37.91	35.02	27.01	23.09	12.55	6.07
Other Operating Activities	83.06	46	-15.16	-72.83	1.02	6.8
Operating Cash Flow	-21.96	-70.94	-120.14	-132.76	-89.08	-39.36
Capital Expenditures	-0.08	-0.11	-0.28	107.98	-0.23	-0.28
Acquisitions	-212.76	-212.76	0	0	0	0
Change in Investments	83.62	125.67	7.98	-40.43	38.1	-127.5
Other Investing Activities	-20	-20	-	-19	-	-
Investing Cash Flow	-149.23	-107.2	7.7	48.55	37.87	-127.78
Share Issuance / Repurchase	212.49	227.15	114.64	9.01	131.87	67.2
Debt Issued / Paid	112.61	109.73	-5.55	64.45	49.58	0
Other Financing Activities	-0.28	-0.28	-	-	-0.16	59.98
Financing Cash Flow	324.82	336.6	109.09	73.47	181.29	127.18
Exchange Rate Effect	-0.21	-0.13	0.01	-0	0.03	-0.03
Net Cash Flow	153.42	158.32	-3.34	-10.75	130.12	-39.99
Free Cash Flow	-22.04	-71.05	-120.41	-24.78	-89.3	-39.64
Free Cash Flow Margin	-9.84%	-38.12%	-156.26%	-129.49%	-	-
Free Cash Flow Per Share	-0.47	-1.74	-3.56	-0.82	-3.54	-3.45

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).